公开(公告)号：US20240360166A1

公开(公告)日：2024-10-31

申请号：US18620978

申请日：2024-03-28

Applicant: Gasherbrum Bio, Inc.

Inventor： Libo CHEN ,  Xiaodong GU ,  Xinglong JIANG

IPC: C07F9/6561 ,  A61K31/675 ,  C07C279/14

CPC classification number: C07F9/6561 ,  A61K31/675 ,  C07C279/14 ,  C07B2200/13

Abstract: The present disclosure relates to salts and solid forms of a compound that are GLP-1 agonists, and its use as a therapeutic agent for treating diseases disorders, or conditions associated with GLP-1, such as type 2 diabetes mellitus (T2DM).

公开(公告)号：US20230391717A1

公开(公告)日：2023-12-07

申请号：US18033414

申请日：2020-10-30

Applicant: JIANGXI SHIMEI PHARMACEUTICAL CO., LTD.

Inventor： Shuimu LIN ,  Shouping LIU ,  Hongxia LI ,  Hong JIANG

IPC: C07C279/14 ,  C07D263/38

CPC classification number: C07C279/14 ,  C07D263/38 ,  C07C2601/16

Abstract: A bakuchiol derivative, a pharmaceutically acceptable salt thereof, and a preparation method and use of the same. The bakuchiol derivative has a structure shown in formula (I):




The above series of amphiphilic antibacterial compounds based on bakuchiol have comparatively excellent antibacterial activities and can overcome the generation of drug resistance of bacteria in drug resistance research simulated in a laboratory.

公开(公告)号：US20190183765A1

公开(公告)日：2019-06-20

申请号：US16216533

申请日：2018-12-11

Applicant: Colgate-Palmolive Company

Inventor： Long PAN ,  Donghui WU ,  Ravi SUBRAMANYAM ,  Hongwei SHEN ,  Chi-Yuan CHENG ,  Tatiana BRINZARI

IPC: A61K8/44 ,  A61Q11/00 ,  A61K31/198 ,  A61K8/21 ,  A61K33/16 ,  A61K31/4172

CPC classification number: A61K8/44 ,  A61K8/19 ,  A61K8/21 ,  A61K8/442 ,  A61K8/445 ,  A61K8/447 ,  A61K8/492 ,  A61K8/4946 ,  A61K31/198 ,  A61K31/4172 ,  A61K33/16 ,  A61K2800/58 ,  A61Q11/00 ,  C07C269/04 ,  C07C271/06 ,  C07C279/14

Abstract: Disclosed herein are amino acid carbamate complexes, methods of synthesis thereof, oral care compositions comprising the same, and methods of making and using thereof.

公开(公告)号：US20180243421A1

公开(公告)日：2018-08-30

申请号：US15962250

申请日：2018-04-25

Applicant: AJINOMOTO CO., INC.

Inventor： Kenji TANAKA ,  Shigekazu KURIHARA ,  Wataru KUROSAWA ,  Hiroshi UMISHIO

IPC: A61K47/18 ,  A61K47/64 ,  A61K9/00

CPC classification number: A61K47/183 ,  A61K9/0019 ,  A61K9/0031 ,  A61K9/0034 ,  A61K9/0043 ,  A61K31/195 ,  A61K47/646 ,  C07C233/47 ,  C07C237/22 ,  C07C279/14

Abstract: Compounds represented by formula (I): defined herein and salts thereof, and compounds represented by formula (II): defined herein and salts thereof, exhibit superior immunostimulatory effects, and are useful as vaccine adjuvants and in vaccines containing such a compound and an antigen.

公开(公告)号：US10039714B2

公开(公告)日：2018-08-07

申请号：US15050416

申请日：2016-02-22

Applicant: NOVOSOM VERWALTUNGS GMBH

Inventor： Steffen Panzner ,  Evgenios Siepi

IPC: A61K9/127 ,  C12N15/88 ,  C07D233/61 ,  C07C279/14 ,  C07C237/22 ,  C07C233/36 ,  C07C233/43 ,  C07C279/12 ,  C07D213/75 ,  C07J41/00 ,  C12N15/113

CPC classification number: A61K9/1272 ,  C07C233/36 ,  C07C233/43 ,  C07C237/22 ,  C07C279/12 ,  C07C279/14 ,  C07D213/75 ,  C07D233/61 ,  C07J41/0055 ,  C12N15/1137 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  Y02P20/582

Abstract: The invention concerns lipid assemblies, liposomes having an outer surface comprising a mixture of anionic and cationic moieties; wherein at least a portion of the cationic moieties are imino moieties that are essentially charged under physiological conditions, and their use for serum resistant transfection of cells.

公开(公告)号：US20170362237A1

公开(公告)日：2017-12-21

申请号：US15186104

申请日：2016-06-17

Applicant: Banavara L. Mylari

Inventor： Banavara L. Mylari

IPC: C07D487/04 ,  C07D417/06 ,  C07C279/14 ,  C07C215/40 ,  C07C229/26 ,  C07C229/24 ,  C07H5/06 ,  C07C279/26

CPC classification number: C07D487/04 ,  C07C215/40 ,  C07C229/24 ,  C07C229/26 ,  C07C279/14 ,  C07C279/26 ,  C07D417/06 ,  C07H5/06

Abstract: The present invention relates to pharmaceutically acceptable water soluble salts of aldose reductase inhibitors, 2-(8-oxo-7-((5-trifluromethyl)-1H-benzo[d]imidazol-2-yl)methyl)7,8-dihydropyrazin[2,3-d]pyridazin-5-yl)acetic acid and [4-oxo-(5-trifluoromethyl-benzothaiazol-2-yl)methyl)-3,4-dihydro-phthalazin-1-yl]-acetic acid (also known as zopolrestat), pharmaceutical compositions thereof and methods of treating diabetic complications in mammals comprising administering to mammals these salt and compositions.

公开(公告)号：US09840530B2

公开(公告)日：2017-12-12

申请号：US14759144

申请日：2013-12-27

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

Inventor： Arup Garu ,  Gopikrishna Moku ,  Sachin Barad Agawane ,  Arabinda Chaudhuri

IPC: A61K39/00 ,  C07H15/04 ,  C07C269/06 ,  A61K47/18 ,  A61K47/26 ,  C07C277/00 ,  A61K9/127 ,  A61K31/166 ,  A61K31/351 ,  A61K31/7105 ,  A61K31/711 ,  A61K45/06 ,  C07C279/14 ,  C07H1/00 ,  C07H13/12

CPC classification number: C07H15/04 ,  A61K9/1271 ,  A61K31/166 ,  A61K31/351 ,  A61K31/7105 ,  A61K31/711 ,  A61K39/00 ,  A61K45/06 ,  A61K47/186 ,  A61K47/26 ,  C07C269/06 ,  C07C277/00 ,  C07C279/14 ,  C07C2601/14 ,  C07C2601/16 ,  C07H1/00 ,  C07H13/12 ,  A61K2300/00

Abstract: The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.

公开(公告)号：US09827217B2

公开(公告)日：2017-11-28

申请号：US15281329

申请日：2016-09-30

Applicant: Rgenix, Inc.

Inventor： Eduardo J. Martinez ,  Andreas G. Grill ,  Aniruddh Singh ,  Padmini Kavuru

IPC: A61K31/197 ,  A61K9/00 ,  A61K47/12

CPC classification number: A61K31/197 ,  A61K9/0019 ,  A61K47/12 ,  C07C57/15 ,  C07C279/14

Abstract: The present invention relates to new pharmaceutical salts of β-GPA which exhibit improved physical properties. In particular, the invention relates to salts of β-GPA with improved flow properties (e.g., improved Carr's index and/or Hausner ratio) such as fumarate salts, succinate salts, and oxalate salts. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of one or more salts of β-GPA, as well as methods of treating cancer including administration of a formulation including a β-GPA salt of the invention to a subject in need thereof.

公开(公告)号：US09790227B2

公开(公告)日：2017-10-17

申请号：US15033433

申请日：2014-10-21

Applicant: LIMITED LIABILITY COMPANY “URAL CENTER OF BIOPHARMACEUTICAL TECHNOLOGY”

Inventor： Oleg Nikolaevich Chupakhin ,  Vladimir Leonidovich Rusinov ,  Evgeny Narcissovich Ulomsky ,  Konstantin Valerievich Savateev ,  Stepan Sergeevich Borisov ,  Natalia Alexandrovna Novikova ,  Svetlana Yakovlevna Loginova ,  Sergey Vladimirovich Borisevich ,  Pavel Vladimirovich Sorokin

IPC: C07D487/04 ,  A61K31/53 ,  C07C279/14

CPC classification number: C07D487/04 ,  A61K31/53 ,  C07C279/14 ,  Y02A50/393

Abstract: The claimed invention relates to the field of biologically active compounds and concerns 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an antiviral effect and is intended for the treatment and prophylaxis of human and animal viral diseases, primarily West Nile Virus, and can be used in the chemical and pharmaceutical industry, in scientific research laboratories and medical facilities, and also in veterinary science. The claimed invention is directed toward achieving the technical result of creating a novel effective drug of the azoloazine variety which exhibits antiviral activity toward a group of RNA-containing viruses, and reducing the dependence of the active compound on cell metabolism. This technical result is achieved in the creation of the novel drug 2-methylsulphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate, which exhibits an aniviral effect and has the formula (I). This technical result is achieved in that a method for producing 2-methylsylphanyl-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide L-arginine dihydrate includes mixing arginine, dissolved in water, and 2-methylthio-6-nitro-7-oxo-1,2,4-triazolo[5,1-c][1,2,4]triazinide sodium dihydrate, dissolved in a (1:1) water-ethanol mixture, whereupon the resultant mixture is boiled then cooled, and the precipitate is filtered off and dried.

公开(公告)号：US09731016B2

公开(公告)日：2017-08-15

申请号：US15089568

申请日：2016-04-03

Applicant: Marina Biotech, Inc.

Inventor： Steven C. Quay ,  Michael E. Houston, Jr. ,  Pierrot Harvie ,  Roger C. Adami ,  Renata Fam ,  Mary Prieve ,  Kathy Fosnaugh ,  Shaguna Seth

IPC: A61K47/18 ,  A61K48/00 ,  C07C235/02 ,  C12N15/88 ,  C07D213/56 ,  C07C279/14 ,  C07D213/40 ,  C07D233/26 ,  C12N15/11 ,  A61K47/44 ,  C12N15/113 ,  A61K31/7088 ,  A61K47/22 ,  C07D233/64 ,  A61K47/28 ,  C07C279/12 ,  A61K9/127

CPC classification number: A61K47/183 ,  A61K9/127 ,  A61K9/1271 ,  A61K9/1272 ,  A61K31/7088 ,  A61K47/18 ,  A61K47/22 ,  A61K47/28 ,  A61K47/44 ,  A61K48/0025 ,  A61K48/0033 ,  C07C235/02 ,  C07C279/12 ,  C07C279/14 ,  C07D213/40 ,  C07D213/56 ,  C07D233/26 ,  C07D233/64 ,  C12N15/111 ,  C12N15/113 ,  C12N15/1131 ,  C12N15/1138 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  Y10S514/943

Abstract: This disclosure provides a range of tyrosine amino acid lipid compounds and compositions useful for drug delivery, therapeutics, and the diagnosis and treatment of diseases and conditions. The amino acid lipid compounds and compositions can be used for delivery of various agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.